Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference
Arcutis Biotherapeutics (Nasdaq: ARQT) announced that President and CEO Frank Watanabe will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference from June 9-11, 2020. Watanabe's presentation is scheduled for June 11, 2020, at 11:10 a.m. PT / 2:10 p.m. ET. The event will be webcast, accessible on the company's website, and an archived replay will be available for 30 days post-conference. Arcutis focuses on developing treatments for immune-mediated dermatological diseases, with ongoing projects that aim to address significant unmet medical needs in this area.
- None.
- None.
WESTLAKE VILLAGE, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that President and CEO Frank Watanabe will participate in a fireside chat during the Goldman Sachs 41st Annual Global Healthcare Conference Webcast taking place June 9-11, 2020.
| Details for the presentation are as follows: |
| Goldman Sachs 41st Annual Global Healthcare Conference Webcast Presentation Date: Thursday, June 11, 2020 Presentation Time: 11:10 a.m. PT / 2:10 p.m. ET |
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Arcutis - Bioscience, applied to the skin.
Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing four novel compounds, including ARQ-151 (topical roflumilast cream); ARQ-154 (topical roflumilast foam); ARQ-252, and ARQ-255 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis, and eczema, vitiligo, and alopecia areata. For more information, please visit www.arcutis.com or follow the Company on LinkedIn.
Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740
FAQ
When will Arcutis Biotherapeutics participate in the Goldman Sachs Healthcare Conference?
Who is the CEO of Arcutis Biotherapeutics?
Is the Goldman Sachs Healthcare Conference presentation available for replay?
What is Arcutis Biotherapeutics focusing on?
What is the stock symbol for Arcutis Biotherapeutics?
